Bacigalupo A, Brand R, Oneto R et al.

Treatment of acquired severe aplastic anemia: bone marrow transplantation ncompared with immunosuppressive therapy – The European Group for Blood and Marrow Transplantation experience.
Seminars in Hematology 2000; 37(1): 69-80.
Description: Compares outcomes of 3,669 patients with aplastic anemia treated in Europe with immunosuppressive therapy or bone marrow transplantation between 1976 and 1998.
PubMed citation number: 10676912

Bacigalupo A, Bruno B, Saracco P et al.

Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony – stimulating factor for severe aplastic anemia: an update of the GITMO/EVMT study on 100 patients.
Blood 2000; 95(6): 1931-1934.
Description: Evaluates 100 patients (median age 16) with severe aplastic anemia. Treatment with antlymphocyte globulin, cyclosporine, prednisolone and granulocyte colony-stimulating factor results in high response raters and overall survival.
PubMed citation number: 10706857

Ball SE, Gibson FM, Rizzo S et al.

Progressive telomere shortening in aplastic anemia
Blood 1998; 91(10): 3582-3592.
Description: Correlation between telomere loss and disease duration in patients with acquired aplastic anemia.
PubMed citation number: 9572992

Brodsky RA, Sensenbrenner LL and Jones RJ.

Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation.
Blood 1996; 87: 491-494.
Description: Treatment with high-dose cyclophosphamide may offer long-term hematologic remission, prevention of relapse, and relatively minimal secondary malignancies.
PubMed citation number: 8555470

Doney K, Leisenring W, Storb R et al.

Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy.
Annals of Internal Medicine 1997; 126(2): 107-115
Description: A comparison of 168 patients who received bone marrow transplantation with 227 patients who received immunosuppressive therapy. Actuarial survival and predictors of survival are emphasized in this study from Seattle.
PubMed citation number: 9005744

Frickhofen N, Heimpel H, Kaltwasser JP et al.

Antithymocyte globulin with or without cyclosporine A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.
Blood 2003; 101(4): 1236-1242.
Description: 11 year follow-up on patients in 1991 study by the German Aplastic Anemia Study Group. Further information on relapse and secondary malignancies.
PubMed citation number: 12393680

Frickhofen N, Kaltwasser JP, Schrezenmeier H et al.

Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine: the German Aplastic Anemia Study Group.
The New England Journal of Medicine 1991; 324(19): 1297-1304.
Description: Randomized, multicenter trial of 84 patients showing benefit to addition of cyclosporine to antilymphocyte globuline and methylprednisolone.
PubMed citation number: 2017225

Gibson FM, Scopes J, Daly S et al.

Haemopoietic growth factor production by normal and aplastic anaemia stroma in long-term bone marrow culture.
British Journal of Haematology 1995; 91(3): 551-561.
Description: Differences in microenvironment of normal bone marrow stroma and stroma of patients with aplastic anemia.
PubMed citation number: 8555053

Kojima S, Horibe K, Inaba J et al.

Long term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation.
British Journal of Haematology 2000; 111(1): 321-328.
Description: 100 children are included in this trial. Up-front bone marrow transplantation results in a significantly better 10-year failure free survival and overall survival than up-front treatment with immunosuppressive therapy.
PubMed citation number: 11091219

Lee KA, Kim SH, Woo HY et al.

Increased frequencies of glutathione S-transferase (GSTMI and GSTTI) gene deletions in Korean patients with acquired aplastic anemia.
Blood 2001; 98(12): 3483-85.
Description: Patients with aplastic anemia have an increased incidence of homozygous deletions of glutathione S-transferase.
PubMed citation number: 11719393

Locasciulli A, van’t Veer L, Bacigalupo A et al.

Treatment with marrow transplantation or immunosuppression of childhood acquired severe aplastic anemia: a report from the EBMT SAA Working Party.
Bone Marrow Transplantation 1990; 6(3): 211-217.
Description: A comparative analysis of 304 children under the age of 15 who received bone marrow transplant or immunosuppression.
PubMed citation number: 2252962

Marsh J, Schrezenmeier H, Marin P et al.

Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporine for treatment of patients with nonsevere aplastic anemia: a report from the European Blood an Marrow Transplant (EBMT) Severe Aplastic Anaemia Workinig Party.
Blood 1999; 93(7): 2191-2195.
Description: Randomized, multicenter trial of 115 patients showing that combination of antithymocyte globulin and cyclosporine is superior to treatment with cyclosporine alone.
PubMed citation number: 10090926

Passweg JR, Socie G, Henterberger W et al.

Bone Marrow transplantation for severe aplastic anemia: has outcome improved?
Blood 1997; 90(2): 858-64.
Description: Comparative survival data on patients with aplastic anemia who received bone marrow transplantation in time cohorts of 1976 – 1980, 1981 – 1987 and 1988 – 1992.
PubMed citation number: 9226187.

Rosenfeld SJ, Kimball J, Vining D et al.

Intensive immunosuppression with antithymocyte globuline and cyclosporine as treatment for severe acquired aplastic anemia.
Blood 1995; 85(11): 3058-3065.
Description: Triple therapy with anithymocyte globulin, methylprednisolone and cyclosporine results in a high response rate when used as first-line therapy in patients with severe acquired aplastic anemia.
PubMed citation number: 7756640

Sloand E, Kim S, Maciejewski JP et al.

Intracellular interferon - gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia.
Blood 2002; 100(4): 1185-1191.
Description: Presence of intracellular intereferon – gamma in T cells of aplastic anemia patients may predict response to immunosuppression and onset of relapse.
PubMed citation number: 12149196

Tisdale JT, Maciejewski JP, Nunez O et al.

Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (CY): follow-up of a randomized trial.
Blood 2002; 100(13): 4668-4670.
Description: Incidence of relapse and secondary malignancies may not be reduced by treatment with high dose cyclophosphamide.
PubMed citation number: 12393567

Young NS and Maciejewski J.

The pathophysiology of acquired aplastic anemia.
The New England Journal of Medicine 1997; 336(19): 1365-1372.
Description: Review Article
PubMed citation number: 9134878

Young Ns and Barrett J.

The treatment of severe acquired aplastic anemia.
Blood 1995; 85(12): 3367-3377.
Description: Review Article
PubMed citation number: 7780125

Return to Table of Contents